Hyperparathyroidism Stocks List

Recent Signals

Date Stock Signal Type
2021-05-13 ABBV New 52 Week Closing High Bullish
2021-05-13 CNCE NR7 Range Contraction
2021-05-13 OPK Stochastic Buy Signal Bullish
2021-05-13 OPK Lower Bollinger Band Walk Weakness
2021-05-13 RMTI NR7 Range Contraction
2021-05-13 RMTI Bollinger Band Squeeze Range Contraction

Recent News for Hyperparathyroidism Stocks

Date Stock Title
May 13 ABBV With Abbvie acquisition, Cantor downgrades Soliton to neutral
May 13 ABBV Forget Walmart, Here Are 3 Better Dividend Stocks
May 12 ABBV AbbVie to Present at the RBC Capital Markets Global Healthcare Conference
May 12 ABBV The Zacks Analyst Blog Highlights: Exxon Mobil, AbbVie, Citigroup, Google and Micron
May 12 ABBV The Best Warren Buffett Stocks to Buy With $300 Right Now
May 11 ABBV 3 Strong Dividend Stocks to Buy for Market Volatility and Inflation Fears
May 11 ABBV Top Analyst Reports for Exxon Mobil, AbbVie & Citigroup
May 11 ABBV AbbVie Enters Growing Market for Tattoo Removal, Cellulite Treatment
May 11 ABBV SOLITON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of SOLY and Encourages Investors to Contact the Firm
May 11 ABBV AbbVie Unit To Acquire Soliton For $550M To Boost Aesthetics Unit
May 10 ABBV SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Soliton, Inc. Buyout
May 10 ABBV SHAREHOLDER ALERT: WeissLaw LLP Investigates Soliton, Inc.
May 10 ABBV Soliton Stock Rallies After $22.60/Share Buyout From AbbVie
May 10 ABBV Soliton rallies on Allergan Aesthetics, AbbVie company, acquisition proposal of $550M
May 10 ABBV Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio
May 10 ABBV 4 Top Healthcare Stocks to Buy Now
May 8 ABBV Is It Too Late to Buy AbbVie Stock in 2021?
May 8 ABBV Better Dividend Stock: AbbVie or Pfizer?
May 7 OPK OPKO Health Enters into Exchange Agreements with Certain 4.5% Convertible Senior Noteholders
May 7 ABBV 7 Warren Buffett Stocks to Buy for the Next Decade

Hyperparathyroidism is an increase in parathyroid hormone (PTH) levels in the blood. This occurs from a disorder either within the parathyroid glands (primary hyperparathyroidism) or outside the parathyroid glands (secondary hyperparathyroidism). Most people with primary disease have no symptoms at the time of diagnosis. When symptoms occur, they are due to elevated blood calcium. With long-standing elevation, the most common symptom is kidney stones. Other symptoms may include bone pain, weakness, depression, confusion, and increased urination. Both primary and secondary may result in osteoporosis (weakening of the bones).In 80% of cases, primary hyperparathyroidism is due to a single benign tumor known as a parathyroid adenoma. Most of the remainder are due to several of these adenomas. Rarely it may be due to parathyroid cancer. Secondary hyperparathyroidism typically occurs due to vitamin D deficiency, chronic kidney disease, or other causes of low blood calcium. The diagnosis of primary hyperparathyroidism is made by finding elevated calcium and PTH in the blood.Primary hyperparathyroidism may be cured by removing the adenoma or overactive parathyroid glands. In those without symptoms, mildly increased blood calcium levels, normal kidneys, and normal bone density monitoring may be all that is required. The medication cinacalcet may also be used to decrease PTH levels. In those with very high blood calcium levels, treatment may include large amounts of intravenous normal saline. Low vitamin D levels should be corrected.Primary hyperparathyroidism is the most common type. In the developed world, between one and four per thousand people are affected. It occurs three times more often in women than men and is typically diagnosed between the ages of 50 and 60. The disease was first described in the 1700s. In the late 1800s, it was determined to be related to the parathyroid. Surgery as a treatment was first carried out in 1925.

More about Hyperparathyroidism
Browse All Tags